** Shares of medical device maker Delcath Systems DCTH.O up 2% at $16.43
** H.C. Wainwright raises PT on DCTH to $29 from $24
** DCTH's intention to enter into a Medicaid National Drug Rebate $(NDRA)$ Agreement "is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth" - Wainwright
** By entering into the NDRA, DCTH's Hepzato kit would be made available to all Medicaid and Medicare Advantage programs, increasing their access considerably
** Company's Hepzato Kit is a drug-device combination product for cancer treatment
** DCTH has begun the process of entering into NDRA and expects it to become effective from Q3 of 2025
** Stock has risen over 34% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.